Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Several recent papers have shown that the miR-34 family of microRNAs is directly involved in mediating the effects of p53, indicating that non-coding RNAs have an important role in tumorigenesis. This Progress article discusses these papers and their implications.
Mixed lineage leukaemia (MLL) has histone methyltransferase activity and regulates the expression of genes such as Hox genes. This activity is lost in MLL fusion proteins resulting from inter-chromosomal translocations, which are leukemogenic. How do MLL fusions function and what is their role in leukaemia stem cells?
Cancer dormancy is a very important yet poorly understood phenomenon in cancer progression. What do we know about the mechanisms of cancer dormancy and can it be targeted therapeutically?
Fox proteins are transcriptional regulators of many biological processes. The authors discuss how these proteins are deregulated in cancer and the roles they have in both tumorigenesis and cancer progression.
How do DNA damage response pathways respond to low levels of DNA damage? Understanding this is essential when assessing environmental cancer risk. This Perspective considers the impact of a negligent G2/M checkpoint on genomic stability and cancer risk.
Gene-directed enzyme–prodrug therapy (GDEPT) aims to improve the therapeutic ratio by increasing tumour cell kill and decreasing systemic toxicity. How is this achieved and how close is this therapy to entering the clinic?
Tumour-induced expansion of regulatory T (TReg) cells is an obstacle to successful cancer immunotherapy. Does it make more sense to suppress the function of these cells rather than deplete them to improve the efficacy of cancer immunotherapy?
